Our Featured Experts

Patrick W. Cobb, MD
William G. Wierda, MD, PhD
Dr. Wierda on Ibrutinib Plus Venetoclax in CLL
William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses a clinical trial exploring the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL).
Oncology Specialists
Publication Bottom Border
Border Publication